We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective Cohort of Children With HIV Infection

This study is currently recruiting participants.
Verified February 2017 by The HIV Netherlands Australia Thailand Research Collaboration
Sponsor:
ClinicalTrials.gov Identifier:
NCT00476606
First Posted: May 22, 2007
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Khon Kaen University
Information provided by (Responsible Party):
The HIV Netherlands Australia Thailand Research Collaboration
May 20, 2007
May 22, 2007
February 24, 2017
March 2003
December 2020   (Final data collection date for primary outcome measure)
1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection [ Time Frame: every 3 months ]
Same as current
Complete list of historical versions of study NCT00476606 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Prospective Cohort of Children With HIV Infection
Treatment Outcome of Children With HIV Infection
To evaluate clinical and immunological outcome of children treated with HAART.
This is a long term cohort study that was started in 2002. Currently, there are 120 children enrolled in the study and are receiving HIV care according to standard practice set by the Thai Ministry of Public Health. HIV-infected parents also receive care at the same clinic.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
PBMC
Non-Probability Sample
HIV-infected infants, children and adolescents (range age 1 day - 20 years old) who have participated in HIV-NAT trials
HIV Infections
  • Drug: Zidovudine, Stavudine, Didanosine, Lamivudine
    Refer to the Thai guideline for HIV management 2007
  • Drug: Nevirapine, Efavirenz
    Refer to the Thai guideline for HIV management 2007
  • Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir
    Refer to the Thai guideline for HIV management 2007
Long-term pediatric cohort
Long-term follow-up cohort since 2003
Interventions:
  • Drug: Zidovudine, Stavudine, Didanosine, Lamivudine
  • Drug: Nevirapine, Efavirenz
  • Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
December 2020
December 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center
  • Children who fulfil criteria to start HAART according to the ATC program
  • Children who are switched to second regimen or salvage therapy
  • Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)
  • Children with HIV infection who are not on antiretroviral therapy
  • Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form

Exclusion Criteria:

  • Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.
Sexes Eligible for Study: All
up to 20 Years   (Child, Adult)
No
Contact: June Ohata, BS, BA 662-652-3040 juneohata4@gmail.com
Thailand
 
 
NCT00476606
HIV-NAT 015
Yes
Not Provided
Not Provided
The HIV Netherlands Australia Thailand Research Collaboration
The HIV Netherlands Australia Thailand Research Collaboration
Khon Kaen University
Principal Investigator: Kiat Ruxrungtham, MD, MSc HIV-NAT, The Thai Red Cross AIDS Research Centre
The HIV Netherlands Australia Thailand Research Collaboration
February 2017